Guillermo Velázquez-Sámano

Guillermo Velázquez-Sámano

Auto-generated profile, based on publicly available information

Guillermo Velázquez-Sámano

Secretaría de Salud, Hospital General de México, Servicio de Alergia e Inmunología Clínica, Ciudad de México

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
EREspiridión Ramos-Martínez
Espiridión Ramos-Martínez
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
WAWarrison Athanasio Andrade
Warrison Athanasio Andrade
JRJorge Rojas-Serrano
Jorge Rojas-Serrano
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
The production of specific neutralizing antibodies by individuals is thought to be the best option for reducing the number of patients with severe COVID-19, which is the reason why multiple vaccines are currently being administered worldwide. We aimed to explore the effect of revaccination with BCG, on the response to a subsequent anti-SARS-CoV-2 vaccine, in persons occupationally exposed to COVID-19 patients. Two groups of 30 randomized participants were selected: one group received a BCG revaccination, and the other group received a placebo. Subsequently, both groups were vaccinated against SARS-CoV-2. After each round of vaccination, the serum concentration of Th1/Th2 cytokines was determined. At the end of the protocol, neutralizing antibodies were determined and the HLA-DRB loci were genotyped. The participants from the BCG group and anti-SARS-CoV-2 vaccine group had increased serum cytokine concentrations (i.e., IL-1β, IL-4, IL-6, IL-12p70, IL-13, IL-18, GM-CSF, INF-γ, and TNF-α) and higher neutralizing antibody titers, compared to the group with Placebo–anti-SARS-CoV-2. Twelve HLA-DRB1 alleles were identified in the Placebo–anti-SARS-CoV-2 group, and only nine in the group revaccinated with BCG. The DRB1*04 allele exhibited increased frequency in the Placebo–anti-SARS-CoV-2 group; however, no confounding effects were found with this allele. We conclude that revaccination with BCG synergizes with subsequent vaccination against SARS-CoV-2 in occupationally exposed personnel.

27 June 2019 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
RCRodrigo Collado-Chagoya
Rodrigo Collado-Chagoya
RCRubén Alejandro Cruz-Pantoja
Rubén Alejandro Cruz-Pantoja
AVAndrea Aida Velasco-Medina
Andrea Aida Velasco-Medina
JRJuan Rosales-Guevara
Juan Rosales-Guevara
Food additives are ingredients that are intentionally added to food in order to modify its physical, chemical, biological, or sensorial characteristics. Food additives may act as allergens and generate IgE-mediated immune reactions, or they may act as pseudo allergens and generate non-IgE-mediated immune reactions. Such reactions can generate diverse clinical pictures or they may exacerbate diseases as diverse as eosinophilic esophagitis, bronchial asthma, atopic dermatitis, contact dermatitis, chronic urticaria, or anaphylaxis. Thousands of food additives are being used daily in industrialized countries and, although their use has been globalized, there is not much science information about their adverse effects; especially about their hypersensitivity reactions that, despite being reported in literature as rare, it is probably because they are under-diagnosed due to the fact that they require a high level of clinical suspicion by the physician, and the proof of a causal connection between the symptomatology and the food additive. Hypersensitivity reactions to food additives must be suspected in patients who report symptoms with the intake of multiple commercially prepared foods or to a commercially prepared food without presenting symptoms with the intake of the natural or homemade version of the same food or with the presence of idiopathic reactions. The diagnostic role of the in vivo or in vitro test against IgE (Skin Tests or RAST) is limited to some natural food additives. The gold standard diagnosis that shows causality between the additive and the symptoms is the oral food challenge. The treatment shall always be the elimination of the food additive from the patient’s diet.

21 May 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
AVAndrea Aida Velasco-Medina
Andrea Aida Velasco-Medina
MGMiguel Leonardo García-León
Miguel Leonardo García-León
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
RWRosa Maria Wong-Chew
Rosa Maria Wong-Chew
Annual influenza vaccination is recommended as a preventive measure for all patients with asthma since asthma exacerbations in children and adults are associated to viral infections including influenza. There is concern about the adequate immune response in asthmatics with ICS treatment. The production of antibodies to influenza in asthmatics has been demonstrated. However, cellular immunity is poorly understood. The aim of the study was to compare the humoral and cellular immune responses to influenza vaccine in asthmatic and healthy subjects. Twenty-five asthmatic patients attending the Allergy and Clinical Immunology Service at the Hospital General de Mexico and 25 healthy adults were included. Blood samples were obtained before, 4 and 12 months after immunization with influenza vaccine, influenza-specific antibodies were determined by the hemagglutination inhibition test and influenza-specific memory B, TCD4+, and TCD8 + lymphocytes were determined by flow cytometry. All the asthmatic patients received ICS treatment. The Geometric Mean titers for all influenza serotypes were similar in both groups; seropositivity and the cellular immune response increased in both groups over time and was comparable. Influenza vaccination in asthmatic patients with immunotherapy and ICS achieved protective antibody levels and cellular immunity over time comparable to healthy subjects.

1 April 2021 in Molecular Immunology
Verified
Journal Article
Closed access
MGMónica Luz Gómez-Esquivel
Mónica Luz Gómez-Esquivel
GFGuillermo Guidos Fogelbach
Guillermo Guidos Fogelbach
MRMaría Isabel Rojo-Gutiérrez
María Isabel Rojo-Gutiérrez
JMJaime Mellado-Abrego
Jaime Mellado-Abrego
MBMario Alberto Bermejo-Guevara
Mario Alberto Bermejo-Guevara
CRCesar A Reyes-Lopez
Cesar A Reyes-Lopez

23 December 2024 in Biomédica
Verified
Journal Article
Open access
PDF file
VGValeria Isabel Valerio Gómez
Valeria Isabel Valerio Gómez
UPUriel Pérez-Blanco
Uriel Pérez-Blanco
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
AVAndrea Aida Velasco-Medina
Andrea Aida Velasco-Medina
AAAntonio Albarrán
Antonio Albarrán
LGLizbeth Blancas Galicia
Lizbeth Blancas Galicia
El STAT1 (Signal Transducer and Activator of Transcription 1) es un factor de transcripción citoplasmático, cuya función es la regulación del crecimiento, la diferenciación, la proliferación, el metabolismo y la apoptosis celular. La vía de señalización JAK/STAT, mediada por el interferón, participa en la eliminación de agentes patógenos intracelulares y virus.Las variantes patógenas de STAT1 pueden producir una función deficiente o incrementada. El aumento de la función o actividad del factor de transcripción STAT1, descrito en el 2011, ocurre por su fosforilación excesiva. Los portadores de estas variantes patogénicas pueden desarrollar enfermedades autoinmunitarias e inflamatorias, y son susceptibles a infecciones por hongos, virus y bacterias. La manifestación temprana y común es la candidiasis mucocutánea crónica.Este reporte trata sobre un paciente, en cuyo primer año de vida, se manifestó un aumento de la función del factor STAT1. Actualmente, tiene 27 años, ha presentado infección por el bacilo de Calmette-Guérin y Mycobacterium tuberculosis, candidiasis mucocutánea crónica, tiña de la cabeza (tinea capitis), y rosácea facial y ocular. Se descartó infección por HIV. Por las manifestaciones clínicas, se sospechó un error innato de la inmunidad, específicamente, con aumento de la función o actividad del STAT1. El diagnóstico se corroboró con la secuenciación de múltiples genes asociados con errores innatos de la inmunidad. En este paciente, se halló la variante patogénica c.961A>G (p.Arg321Gly) en el gen STAT1, previamente reportada como una mutación de aumento de la función.

4 July 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
MAMariana Esther Arroyo-Cruz
Mariana Esther Arroyo-Cruz
RCRodrigo Collado-Chagoya
Rodrigo Collado-Chagoya
JHJavier Hernández-Romero
Javier Hernández-Romero
AAAlejandro Eliosa Alvarado-Gumaro
Alejandro Eliosa Alvarado-Gumaro
AGAna del Carmen García-González
Ana del Carmen García-González
GVGuillermo Velázquez-Sámano
Guillermo Velázquez-Sámano
Background: The prevalence of latex allergy ranges from 0.8 to 6.5% and is the second cause of perioperative anaphylaxis. The main risk factors are being a health worker or latex producer, hours of latex gloves or products usage, exposure to other hand irritants, history of atopy, neural tube closure defects or numerous surgeries at early age.Objective: To determine the frequency of latex sensitization in resident physicians of the Hospital General de México surgical area.Methods: Prospective, cross-sectional, descriptive study where skin prick tests were applied to residents of the surgical area of the Hospital General de México, which depends on the Ministry of Health and is located in Mexico City.Results: Ninety-two subjects were included and had skin tests practiced, with 11 surgical specialties participating. Latex sensitization in this population was 11.9%, whereas the presence of latex allergy was 10.8%.Conclusions: A high frequency of latex sensitization and allergy was demonstrated in Hospital General de Mexico surgery residents, which indicates the need for policies and procedures to be developed for health workers with latex allergy, as well as continuous training of employees on latex allergy.